<DOC>
	<DOCNO>NCT01228383</DOCNO>
	<brief_summary>Study design : Single-blind ( subject observer-blinded ) , active-controlled , randomized [ 6:2:1:2:1 ; CL184 + purify vero cell rabies vaccine ( PVRV ) vs. human rabies immune globulin ( HRIG ) + PVRV vs. placebo + PVRV vs. CL184 + human diploid cell vaccine ( HDCV ) vs. placebo + HDCV ] , mono-center study Study objective : Primary : To evaluate safety CL184 combination PVRV healthy adult subject . Secondary : To evaluate safety HRIG placebo combination PVRV evaluate safety CL184 placebo combination HDCV healthy adult subject . To evaluate rabies virus neutralize activity ( RVNA ) administration CL184 placebo combination PVRV , HRIG combination PVRV , CL184 placebo combination HDCV healthy adult subject . To evaluate pharmacokinetics monoclonal antibody ( mAbs ) .</brief_summary>
	<brief_title>Rabies Virus Neutralizing Activity Safety CL184 , Monoclonal Antibody Cocktail , Simulated Rabies Post-Exposure Prophylaxis Healthy Adults</brief_title>
	<detailed_description>This study design explore obtain safety RVNA data CL184 comparison HRIG placebo part classical post-exposure prophylaxis ( PEP ) regimen . This regimen apply simulated PEP regimen healthy subject ( i.e . pre-exposure setting ) study . A comparison placebo combine rabies vaccine include differentiate contribution immune globulin vaccine investigate potential interaction immune globulin vaccine . RVNA provide CL184 HRIG , well vaccination response check regularly study booster dos apply study , necessary . In addition pharmacokinetic data collect .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female subject age ≥18 ≤55 year Subjects free obvious healthproblems stable condition medication Body mass index ≥18 ≤30 kg/m2 Abstinence sexual intercourse use adequate contraception date screen Day 90 Male subject must agree donate sperm first checkin Day 90 Subject sign write informed consent Prior history active passive rabies immunization Clinically significant acute illness infection include fever ( ≥38 °C ) within 2 week first dose History and/or family history clinically significant immunodeficiency autoimmune disease Planned immunization live vaccine come 3 month first dose Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Rabies</keyword>
	<keyword>Post-exposure prophylaxis</keyword>
</DOC>